

## CONSENSUS STATEMENT

## OPEN



# The urgency to regulate validation of automated blood pressure measuring devices: a policy statement and call to action from the world hypertension league

James E. Sharman <sup>1,2</sup>✉, Pedro Ordunez <sup>3</sup>, Tammy Brady <sup>4</sup>, Gianfranco Parati <sup>5,6</sup>, George Stergiou <sup>7</sup>, Paul K. Whelton <sup>8</sup>, Raj Padwal <sup>9</sup>, Michael Hecht Olsen <sup>2,10,11</sup>, Christian Delles <sup>2,12,13</sup>, Aletta E. Schutte <sup>2,14,15</sup>, Maciej Tomaszewski <sup>15,16,17</sup>, Daniel T. Lackland <sup>18</sup>, Nadia Khan <sup>15,19</sup>, Richard J. McManus <sup>13,20</sup>, Ross T. Tsuyuki <sup>21</sup>, Xin-Hua Zhang <sup>22,23</sup>, Lisa D. Murphy <sup>24</sup>, Andrew E. Moran <sup>25</sup>, Markus P. Schlaich <sup>26,27</sup> and Norm R. C. Campbell <sup>28</sup>

© The Author(s) 2022

*Journal of Human Hypertension*; <https://doi.org/10.1038/s41371-022-00747-0>

This policy statement is intended to be used as a resource for all health professionals and civil society, including regulatory agencies, Ministries of Health and healthcare organizations, to accelerate the availability, affordability, and exclusive use of automated blood pressure measuring devices (BPMDS) that have passed adequate clinical validation testing. In line with guidance from the World Health Organization (WHO) medical device technical series [1], the term clinical validation is the process by which devices are tested for accuracy in healthy people and patients with hypertension, and a clinically validated BPMD is one that has “undergone rigorous, standardized testing against a gold standard [properly calibrated manual auscultatory measurement] to ensure that the device produces accurate measurements” [1] to an internationally accepted standard.

Most automated BPMDS that are marketed for sale globally have not undergone adequate validation testing to ensure clinical accuracy [2–4]. The primary recommendation of this policy statement is for convergence towards the global regulatory requirement for mandatory, independent clinical validation of automated BPMDS according to an agreed universal standard [5, 6]. This will ensure that the accuracy of automated BPMDS is confirmed before being cleared for sale by regulatory authorities, and is an urgent international need advocated by the World

Hypertension League, the Lancet Commission on Hypertension and other organizations including the WHO [1, 7, 8].

## RATIONALE SUPPORTING THE URGENCY TO REGULATE VALIDATION

High systolic BP contributes to more than 10 million deaths each year and is the single most important modifiable risk factor for cardiovascular disease (CVD) [9]. Controlling hypertension is a global priority to reduce death and disability and subsequent economic costs from CVD [10]. The WHO has advocated for a strategic public health approach to the control of hypertension and developed a series of technical documents, including the HEARTS technical package [11], to assist governments and others engaged in the management of high BP. A foundational aspect to the detection, diagnosis, treatment and control of hypertension is reliable diagnosis which requires an accurate and reproducible method for measuring BP. Critical factors to achieve this include patient preparation, a suitable measurement environment, training and certification of health providers, use of a standardized technique/protocol, and an accurate and precise (preferably automated) BPMD [12].

Automated BPMDS that have been clinically validated for accuracy are widely recommended to be used in favor of manual

<sup>1</sup>Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia. <sup>2</sup>Lancet Commission on Hypertension Group, London, UK. <sup>3</sup>Department of Non Communicable and Mental Health, Pan American Health Organization, Washington, DC, USA. <sup>4</sup>Department of Pediatrics, Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. <sup>5</sup>Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy. <sup>6</sup>Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. <sup>7</sup>Hypertension Center STRIDE-7, National and Kapodistrian University of Athens, School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece. <sup>8</sup>Departments of Epidemiology and Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA. <sup>9</sup>Department of Medicine, University of Alberta, Edmonton, AB, Canada. <sup>10</sup>Department of Internal Medicine, Holbaek Hospital, Holbaek, Denmark. <sup>11</sup>Department for Regional Health Research, University of Southern Denmark, Odense, Denmark. <sup>12</sup>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. <sup>13</sup>British and Irish Hypertension Society, Edinburgh, Scotland, UK. <sup>14</sup>School of Population Health, University of New South Wales, The George Institute for Global Health, Sydney, NSW, Australia. <sup>15</sup>International Society of Hypertension, White Colne, UK. <sup>16</sup>Division of Cardiovascular Sciences, Faculty of Medic2ine, Biology and Health, University of Manchester, Manchester, UK. <sup>17</sup>Manchester Heart Centre and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK. <sup>18</sup>Division of Translational Neurosciences and Population Studies, Department of Neurology, Medical University of South Carolina, Charleston, SC, USA. <sup>19</sup>Department of Medicine, Center for Health Evaluation and Outcomes Sciences, University of British Columbia, Vancouver, BC, Canada. <sup>20</sup>Nuffield Department Primary Care Health Sciences, University of Oxford, Oxford, UK. <sup>21</sup>Hypertension Canada, Toronto, ON, Canada. <sup>22</sup>World Hypertension League, Hong Kong, China. <sup>23</sup>Beijing Hypertension League Institute, Beijing, China. <sup>24</sup>Stroke Foundation, Melbourne, VIC, Australia. <sup>25</sup>Resolve to Save Lives, New York, NY, USA. <sup>26</sup>High Blood Pressure Research Council of Australia, Melbourne, VIC, Australia. <sup>27</sup>Dobney Hypertension Centre, Royal Perth Hospital Research Foundation, Medical School, University of Western Australia, Perth, WA, Australia. <sup>28</sup>Department of Medicine, Physiology and Pharmacology and Community Health Sciences, O'Brien Institute for Public Health and Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada.

✉email: James.Sharman@utas.edu.au

Received: 3 July 2022 Revised: 19 July 2022 Accepted: 2 August 2022  
Published online: 07 December 2022

**Table 1.** Recommendations for government policies on automated BP measuring devices (BPMDs)<sup>a</sup>.

Build strong regulatory capacity to ensure a smooth and rapid transition to the sole use of validated automated BPMDs for routine clinical use within a strategic approach to hypertension/cardiovascular disease/non-communicable disease prevention and control, emphasizing primary healthcare facilities.
Develop national capacity for independent validation testing of all automated BPMDs, preventing conflicts of interest.
Enable universal access to validation testing protocols and develop checklist/s to provide evidence that validation testing protocols have been followed. This should include a process of regular review and updating.
Regulate the sales (including those online) of automated BPMDs to prohibit the marketing of clinical devices that have either failed validation testing or have not undergone validation testing or where "equivalence" to a validated BPMD is not clearly proven.
Regulate the sale and marketing of automated BPMDs to require packaging that clearly and prominently indicates whether the device has passed validation testing, and for which population (e.g., general population, pregnancy, large arm circumference, atrial fibrillation, children).
Develop an easy-to-access list of validated (including equivalent) automated BPMDs that are readily available in each region. Ensure that this list is regularly reviewed.
Develop policies to ensure equitable and affordable access to validated automated BPMDs including locations where electricity is unreliable.
Develop a procurement policy that includes only validated automated BPMDs for routine clinical use.
Develop technical capacity (e.g., clinical engineers) to appropriately select, maintain and support the use of validated automated BPMDs.

<sup>a</sup>Adapted from ref. [1].

auscultatory BP measurement methods because the automated component removes observer-related barriers to accurate BP measurement [13, 14]. Automated BPMDs without evidence of having been properly validated for accuracy have greater measurement variability, are less likely to pass static pressure testing, and are more likely to be inaccurate [15–18]. A Canadian study demonstrated that non-validated devices were associated with clinically meaningful discrepancies in measured BP: a > 5 mmHg discrepancy in 69% of patients and >10 mmHg discrepancy in 36% of patients relative to accurately measured BP [19]. Currently, these inadequately validated devices are also commonly used by healthcare providers and by patients for home BP measurement [17, 18], and thus probably contribute to incorrect hypertension diagnosis and management in many individuals. At a population level, even small errors (e.g., 5 mmHg) in systolic or diastolic BP measurement can lead to misclassification of millions of people [2, 12].

The main consequences of inaccurate BP measurement are incorrect diagnosis and deficient medical management, including inappropriate drug treatment. This may manifest as excessive, over-medication for those incorrectly labeled as hypertensive, or lack of or under treatment with therapies proven to reduce CVD events for those incorrectly labeled as normotensive [20]. The above examples of unsafe clinical care lead to increased healthcare risks and also costs that could otherwise be avoided [2, 21–23]. Current estimates indicate that 75–80% of automated BPMDs marketed globally do not have evidence of being adequately clinically validated for accuracy [3, 4]. This is enabled through various regulatory loopholes, and seriously undermines efforts to perform best practice clinical care and efficient CVD prevention [7, 24, 25].

The wide availability of inadequately validated BPMDs also conflicts with essential principles regarding the design and production of medical devices. Specifically, the concept that medical devices must provide accurate measurements, must not compromise an individual's clinical condition or safety, and must have benefits of use that outweigh any undesirable effects arising from its use [26, 27]. International hypertension societies support the WHO recommendation that adequately validated automated BPMDs must be used in routine clinical management of hypertension [13, 14, 28–31]. There have also been calls to strengthen regulations on the manufacture and marketing of automated BPMDs to address loopholes that allow insufficient proof of accuracy testing [7, 24, 32, 33]. But despite these efforts the global production of inadequately validated automated

BPMDs continues to rise in a multibillion-dollar industry, with large annual market growths forecast [34].

Although well-known BP manufacturers support strengthening quality standards for validating automated BPMDs [35], current estimates indicate there could be at least 450 manufacturers producing >3500 unique models, most of which are not validated [3]. Redressing this major international problem requires urgent, consistent and global policy action by government regulatory organizations [36, 37]. The WHO developed a document to guide governments in developing policies that include regulations for automated BPMDs [1]. This document recommends that for routine clinical purposes, including office, ambulatory and home monitoring of BP, that only cuff automated BP devices that have passed accepted international accuracy standards be used (e.g., currently the International Organization for Standardization 81060-2; 2018 protocol) and with validation testing conducted by qualified investigators, independent from the manufacturers.

## RECOMMENDED GOVERNMENTAL POLICIES

A wide array of government and societal policies are required to ensure the smooth and rapid transition to only allowing the sale of properly validated automated BPMDs. Governments with a strategy for hypertension/CVD/non-communicable disease control will be able to coordinate the development and implementation of needed policies more efficiently. Table 1 provides policy recommendations that governments need to adapt rapidly to ensure only properly validated automated BPMDs are used in routine clinical practice.

## WHAT CAN CLINICIANS, CIVIL SOCIETY, AND THEIR ORGANIZATIONS DO?

Governments may act independently to implement the recent WHO recommendations [1] regarding automated BPMDs, however, the WHO first recommended exclusive use of validated BPMD almost two decades ago [38] and this remains widely unimplemented. Hence, strong advocacy and watchdog action from outside of government is needed to accelerate uptake of the WHO report recommendations [1]. Advocating for and developing a strategic plan to improve hypertension/CVD/non-communicable disease control that includes the rapid transition to sole use of adequately validated automated BPMDs is important.

Adapting this Policy Statement and Call to Action at a national level for use in advocacy is likely to have a larger impact than a

global call to action that does not account for the national context. Securing the support of all key national organizations (e.g., stroke and heart foundations, CVD organizations, primary care, important civil society organizations) and forming a health coalition that sustains advocacy actions until government implementation of policies are key to success.

Education of healthcare professionals and the public is also likely to be pivotal. Extensive and global field experience of the authors, as well as recent data [37, 39], indicates that many clinicians are not aware that most automated BPMDs are not properly validated, nor do they recognize the need to routinely use validated automated BPMDs in clinical practice. This deficit in knowledge may undermine advocacy and implementation efforts. Health organizations and civil society can work with accreditation authorities to ensure education and certification throughout training and practice, to provide consistent messaging regarding the need to rapidly transition to the routine use of validated automated BPMDs. All facilities that require accreditation must have adequately validated automated BPMDs available for routine clinical use.

## THE WAY FORWARD

Developing and implementing regulations for the exclusive use of automated validated BPMDs is urgent and a technical imperative. However, it is a complex process requiring political will and coordination of multiple actors at the national and global levels. Civil society and professional and academic organizations play a fundamental role in this context. This process must be a well-planned, progressive and participatory process. Implementation should be gradual to ease acceptance, allow time for realistic replacement of manual BPMDs (and those that are not validated), avoid high costs, and avoid challenges for manufacturers and distributors [39].

For instance, in the region of the Americas, 22 countries led by the Ministries of Health, in collaboration with local stakeholders and the Pan American Health Organization (PAHO), have initiated a set of actions to improve the regulatory landscape and update the procurement mechanisms to promote the exclusive use of validated automated BPMDs [36] with an emphasis in primary healthcare, where most of the persons with hypertension and other non-communicable diseases are managed. These actions have been coordinated through the HEARTS in the Americas program, which is a comprehensive risk reduction model of hypertension and CVD risk management implemented across the region [40, 41]. An important first step was to understand the regulatory frameworks governing the accuracy of automated BPMDs across different countries. These frameworks were found to be weak, fragmented, and lacking both policies and regulations to promote the exclusive use of validated automated BPMDs [32].

Other steps involved creating awareness through technical meetings with regulatory authorities and Ministries of Health to explore actions to strengthen regulations and create resources to assist policy makers, health professionals, regulatory agencies, professional societies, and the public [42]. Training workshops were provided on conducting validation studies to build national capacity in specific countries and practical guides have been published [43]. Information on finding validated automated BPMDs was published [44] and technical resources were listed on the PAHO website [45, 46]. PAHO also published a guidance document to contribute to meeting these recommendations by providing a practical tool for governments to improve their national regulatory frameworks to improve accuracy of automated BPMDs, in turn contributing to the exclusive use of validated automated BPMDs in primary healthcare facilities by 2025 [40].

In conclusion, accelerating the uptake of adequately validated automated BPMDs for routine clinical use is important in the global and national strategy to enhance hypertension/CVD/non-communicable disease control. This effort is consistent with WHO

recommendations [1] as well as the global commitment to remove all mercury containing medical devices, including sphygmomanometers, because of its environmental hazard. Equally compelling is the extensive data indicating that manual auscultatory aneroid BP devices are often out of calibration, lack maintenance, and are rarely tested for calibration in clinical practice [47, 48]. The main weakness of automated BPMDs is the lack of regulatory requirements to validate devices for accuracy and precision before receiving regulatory clearance to market and sell. This policy statement is intended to be used, but not limited, by national health and civil society members and organizations in advocacy—and watchdog—to support governments developing and implementing policies, including regulations to accelerate the routine use of appropriately validated automated BPMDs in clinical practice.

## DISCLAIMER

PO is a staff member of the Pan American Health Organization. HEARTS in the Americas is an initiative of the Pan American Health Organization. However, the authors alone are responsible for the views expressed in this article; those views do not necessarily represent those of the Pan American Health Organization.

## REFERENCES

- WHO technical specifications for automated non-invasive blood pressure measuring devices with cuff. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
- Whelton PK, Picone DS, Padwal R, Campbell NRC, Drawz P, Rakotz MK, et al. Global proliferation and clinical consequences of non-validated automated BP devices. *J Hum Hypertens.* 2022. <https://doi.org/10.1038/s41371-022-00667-z>. Online ahead of print.
- Picone DS, Campbell NRC, Schutte AE, Olsen MH, Ordunez P, Whelton PK, et al. Validation status of blood pressure measuring devices sold globally. *JAMA.* 2022;327:680–1.
- Picone DS, Deshpande RA, Schultz MG, Fonseca R, Campbell NRC, Delles C, et al. Nonvalidated home blood pressure devices dominate the online marketplace in Australia. *Hypertension.* 2020;75:1593–9.
- International Organization for Standardization. ISO 81060-2:2018. Non-invasive sphygmomanometers—Part 2: Clinical investigation of intermittent automated measurement type. Accessed 7 Dec 2018. <https://www.iso.org/standard/73339.html>.
- Ringrose JS, Padwal R. Automated blood pressure measuring devices: how are they validated for accuracy? *J Hum Hypertens.* (2022). <https://doi.org/10.1038/s41371-022-00761-2>.
- Campbell NR, Gelfer M, Stergiou GS, Alpert BS, Myers MG, Rakotz MK, et al. A call to regulate manufacture and marketing of blood pressure devices and cuffs: a position statement from the world hypertension league, international society of hypertension and supporting hypertension organizations. *J Clin Hypertens.* 2016;18:378–80.
- Sharman JE, O'Brien E, Alpert B, Schutte AE, Delles C, Hecht Olsen M, et al. Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. *J Hypertens.* 2020;38:21–9.
- Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbas-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020;396:1223–49.
- Campbell NRC, Schutte AE, Varghese CV, Ordunez P, Zhang XH, Khan T, et al. Sao Paulo call to action for the prevention and control of high blood pressure: 2020. *J Clin Hypertens.* 2019;21:1744–52.
- World Health Organization. Hearts: technical package for cardiovascular disease management in primary health care. World Health Organization. 2016. <https://apps.who.int/iris/handle/10665/252661>.
- Padwal R, Campbell NRC, Schutte AE, Olsen MH, Delles C, Etyang A, et al. Optimizing observer performance of clinic blood pressure measurement: a position statement from the Lancet Commission on Hypertension Group. *J Hypertens.* 2019;37:1737–45.
- Muntner P, Einhorn PT, Cushman WC, Whelton PK, Bello NA, Drawz PE, et al. Blood pressure assessment in adults in clinical practice and clinic-based research: JACC scientific expert panel. *J Am Coll Cardiol.* 2019;73:317–35.
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J.* 2018;2018:3021–104.

15. Hodgkinson JA, Lee MM, Milner S, Bradburn P, Stevens R, Hobbs FR, et al. Accuracy of blood-pressure monitors owned by patients with hypertension (ACCU-RATE study): a cross-sectional, observational study in central England. *Br J Gen Pract.* 2020;70:e548–54.
16. Akpolat T, Aydogdu T, Erdem E, Karatas A. Inaccuracy of home sphygmomanometers: a perspective from clinical practice. *Blood Press Monit.* 2011;16:168–71.
17. Akpolat T, Dilek M, Aydogdu T, Adibelli Z, Erdem DG, Erdem E. Home sphygmomanometers: validation versus accuracy. *Blood Press Monit.* 2009;14: 26–31.
18. Jung MH, Kim GH, Kim JH, Moon KW, Yoo KD, Rho TH, et al. Reliability of home blood pressure monitoring: in the context of validation and accuracy. *Blood Press Monit.* 2015;20:215–20.
19. Ringrose JS, Polley G, McLean D, Thompson A, Morales F, Padwal R. An assessment of the accuracy of home blood pressure monitors when used in device owners. *Am J Hypertens.* 2017;30:683–9.
20. Campbell NR, McKay DW. Accurate blood pressure measurement: why does it matter? *CMAJ.* 1999;161:277–8.
21. Campbell NR, Padwal R, Picone DS, Su H, Sharman JE. The impact of small to moderate inaccuracies in assessing blood pressure on hypertension prevalence and control rates. *J Clin Hypertens.* 2020;22:939–42.
22. Desson Z, Sharman JE, Ramanathan S. Potential return on investment in a translational research project aimed at improving the accuracy of blood pressure measuring devices in Australia. *J Hum Hypertens.* In press.
23. Jones DW, Appel LJ, Sheps SG, Roccella EJ, Lenfant C. Measuring blood pressure accurately: new and persistent challenges. *JAMA.* 2003;289:1027–30.
24. Alpert BS. Can 'FDA-cleared' blood pressure devices be trusted? A call to action. *Blood Press Monit.* 2017;22:179–81.
25. Sharman JE, Padwal R, Campbell NR. Global marketing and sale of accurate cuff blood pressure measurement devices. *Circulation.* 2020;142:321–3.
26. Therapeutic Goods (Medical Devices) Regulations. 2002. [http://classic.austlii.edu.au/au/legis/cth/consol\\_reg/tgdr2002400/notes.html](http://classic.austlii.edu.au/au/legis/cth/consol_reg/tgdr2002400/notes.html). Accessed 19 Jan 2022.
27. WHO global model regulatory framework for medical devices including in vitro diagnostic medical devices. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
28. Parati G, Stergiou GS, Bilo G, Koliass A, Pengo M, Ochoa JE, et al. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. *J Hypertens.* 2021;39:1742–67.
29. Stergiou G, Parati G, Imai Y, McManus R, Head G, Kario K, et al. Guidelines for Home Blood Pressure Monitoring. In: Stergiou G, Parati G, Mancia G, editors. *Home Blood Pressure Monitoring (European Society of Hypertension)*: Springer International Publishing; Cham, Switzerland; 2019. p. 165–71.
30. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/APA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension.* 2017;2018:e13–5.
31. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. International Society of Hypertension global hypertension practice guidelines. *J Hypertens.* 2020;2020:982–1004.
32. Lombardi C, Sharman JE, Padwal R, Picone D, Alcolea E, Ayala R, et al. Weak and fragmented regulatory frameworks on the accuracy of blood pressure-measuring devices pose a major impediment for the implementation of HEARTS in the Americas. *J Clin Hypertens.* 2020;22:2184–91.
33. O'Brien E, Stergiou GS, Turner MJ. The quest for accuracy of blood pressure measuring devices. *J Clin Hypertens.* 2018;20:1092–5.
34. Blood Pressure Monitoring Devices Market Size, Share & Trends Analysis Report By Product (Sphygmomanometers/Aneroid BP Monitors, Ambulatory BP Monitors), By End-use, By Region, And Segment Forecasts, 2021. 20282021. Report No.: 978-1-68038-586-1.
35. Li J, Frick G, Herberigs K, Matsumura P, Sarkis J, Verberk WJ, et al. Industry perspectives on the global use of validated blood pressure measuring devices. *J Hum Hypertens.* 2022. <https://doi.org/10.1038/s41371-022-00717-6>. Online ahead of print.
36. Ordunez P, Lombardi C, Picone DS, Brady TM, Campbell NRC, Moran AE, et al. HEARTS in the Americas: a global example of using clinically validated automated blood pressure devices in cardiovascular disease prevention and management in primary health care settings. *J Hum Hypertens.* 2022. <https://doi.org/10.1038/s41371-022-00659-z>. Online ahead of print.
37. Lombardi C, Picone D, Sharman JE, Campbell NR, Farias RF, Guerre S, et al. Country experiences on the path to exclusive use of validated automated blood pressure measuring devices within the HEARTS in the Americas Initiative. *J Hum Hypertens.* 2022 Jul 11. <https://doi.org/10.1038/s41371-022-00706-9>. Online ahead of print.
38. Affordable technology: Blood pressure measuring devices for low resource settings. Geneva: World Health Organisation; 2005.
39. Picone DS, Peterson GM, Jackson SL, Campbell NRC, Delles C, Olsen MH, et al. Perceptions of pharmacists on the quality of automated blood pressure devices: a national survey. *J Hum Hypertens.* 2022 Mar 21. <https://doi.org/10.1038/s41371-022-00670-4>. Online ahead of print.
40. HEARTS in the Americas Regulatory Pathway to the Exclusive Use of Validated Blood Pressure Measuring Devices. Washington, D.C: Pan American Health Organization; 2021. License: CC BY-NC-SA 3.0 IGO. <https://doi.org/10.37774/9789275124864>.
41. Pan American Health Organization HEARTS in the Americas. Accessed 5 April 2022. <https://www.paho.org/en/hearts-americas>.
42. Pan American Health Organization and World Health Organization; HEARTS in the Americas: Blood Pressure Measurement. Accessed 13 Jan 2022. <https://www.paho.org/en/hearts-americas/hearts-americas-blood-pressure-measurement>.
43. Stergiou GS, Palatini P, Asmar R, Ioannidis JP, Koliass A, Lacy P, et al. Recommendations and Practical Guidance for performing and reporting validation studies according to the Universal Standard for the validation of blood pressure measuring devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO). *J Hypertens.* 2019;37:459–66.
44. Picone DS, Padwal R, Campbell NRC, Boutouyrie P, Brady TM, Olsen MH, et al. How to check whether a blood pressure monitor has been properly validated for accuracy. *J Clin Hypertens.* 2020;22:2167–74.
45. Pan American Health Organization Lists of validated automated blood pressure measuring devices. Accessed 5 April 2022. <https://www.paho.org/en/documents/lists-validated-automated-blood-pressure-measuring-devices>.
46. Pan American Health Organization Technical resources relevant to the accuracy of blood pressure measurement. Accessed 5 April 2022. <https://www.paho.org/en/documents/technical-resources-relevant-accuracy-blood-pressure-measurement>.
47. de Greeff A, Lorde I, Wilton A, Seed P, Coleman AJ, Shennan AH. Calibration accuracy of hospital-based non-invasive blood pressure measuring devices. *J Hum Hypertens.* 2010;24:58–63.
48. A'Court C, Stevens R, Sanders S, Ward A, McManus R, Heneghan C. Type and accuracy of sphygmomanometers in primary care: a cross-sectional observational study. *Br J Gen Pract.* 2011;61:e598–603.

## ACKNOWLEDGEMENTS

This paper is a policy statement of the World Hypertension League. The following parties endorse this policy statement: World Hypertension League, Lancet Commission on Hypertension Group, International Society of Hypertension, Hypertension Canada, British and Irish Hypertension Society, Stroke Foundation—Australia, High Blood Pressure Research Council of Australia and Resolve to Save Lives.

## AUTHOR CONTRIBUTIONS

Conception and paper drafting was led by JES, PO, and NRCC. All authors made substantial contributions to the work, including revision of drafts, and all authors have approved the submitted version.

## FUNDING

Open Access funding enabled and organized by CAUL and its Member Institutions.

## COMPETING INTERESTS

TMB is co-chair of the Association for the Advancement of Medical Instrumentation Sphygmomanometer committee. TMB is co-chair of the American Medical Association's Validated Device Listing Independent Review Committee. TMB has also received funding research or salary support from Resolve to Save Lives. Resolve to Save Lives is funded by Bloomberg Philanthropies, the Bill and Melinda Gates Foundation, and Gates Philanthropy. RJM's employer (University of Oxford) receives licensing and consulting fees from Omron and Sensyne for telemonitoring solutions developed from his research. NRCC reports personal fees from Resolve to Save Lives, the Pan American Health Organization, the World Bank and Switch Health Inc. outside the submitted work; and is an unpaid member of World Action on Salt, Sugar, and Health and an unpaid consultant on dietary sodium and hypertension control to numerous governmental and non-governmental organizations. RP is CEO of mmHg, provider of digital health and software services, including remote patient monitoring software. AES is on the Executive Management Board of STRIDE BP and is co-author of the World Health Organization's technical specifications of blood pressure devices. JES is a consultant of HEARTS in the Americas, an initiative of the Pan American Health Organization. JES is principal investigator of a National Health and Medical

Research Council partnership grant (S0026615) that includes a medical technology company that manufactures a central blood pressure monitor. MPS has received research support from Medtronic, Abbott, Metavention, Recor, and Boehringer Ingelheim and personal fees/travel support from Medtronic and Abbott. GSS is chairing the STRIDE BP organization for blood pressure measurement methods and devices, conducted validation studies of blood pressure monitors, and advised manufacturers on device and software development. MT has received unrestricted gift in kind from Omron for the purpose of a clinical study. None of the other authors have disclosures.

## ADDITIONAL INFORMATION

**Correspondence** and requests for materials should be addressed to James E. Sharman.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022